Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7237
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Detroit, Michigan. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 25–36 of 7,237 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

NCT04166409
View directory record Official record
Conditions
Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions
Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
124
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Recruiting Phase 1 Interventional

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

NCT05950464
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Tuvusertib, X-Ray Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

NCT05554406
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
216
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Suspended Phase 2Phase 3 Interventional

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

NCT05691478
View directory record Official record
Conditions
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions
Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
1,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Active, not recruiting Phase 4 Interventional

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

NCT06453213
View directory record Official record
Conditions
Focal Onset Seizure
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

NCT01856192
View directory record Official record
Conditions
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
502
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma, c-MET
Interventions
Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Recruiting No phase listed Observational

Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

NCT06964685
View directory record Official record
Conditions
AMI Cardiogenic Shock
Interventions
Impella
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Jonesboro, Arkansas • Orange, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
226
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Active, not recruiting Phase 3 Interventional

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
7,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
122
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

NCT02642042
View directory record Official record
Conditions
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Docetaxel, Laboratory Biomarker Analysis, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
596
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Jonesboro, Arkansas + 375 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 1:43 PM EDT